Terns Pharmaceuticals Inc. (NASDAQ:TERN)

There are currently no videos for this stock.
To request coverage of this stock, please click the green request video box on the right.
Bands Volume 200 SMA 50 SMA 20 SMA Videos Alerts Articles Events
TERN Weekly Chart

Old Forum Content for TERN

Make a Forum Post
Become a member to view recent forum posts. Already a member? Sign in here.
Loading...
  • Bitman320: @woodman $VKTX Great to have you back. I’m holding $VKTX for the long term, in it from way below. Any thoughts on $TERN, $INZY or $CLRB
  • woodman: @Bitman320 $VKTX $TERN $INZY $CLRB - I sold nearly all my $INZY on Fri 4/5 & Mon 4/8, leaving only a very small position - placeholder essentially (I was scared off by $EFTR's clobbering). I still have a smallish position in $CLRB. I have no posi ...
  • MongosPawn: @woodman $VKTX $TERN $INZY $CLRB $EFTR $ARDX $XFOR $XBI Took a small starter in $XBI, Added small to $XFOR this morning.
  • woodman: #Obesity drug targets $VKTX $TERN $GPCR et al. - Big Pharma companies are on the hunt! https://www.usnews.com/news/top-news/articles/2024-01-11/drugmakers-plot-way-into-obesity-market-with-deals-and-development
  • traderbren: $TERN - NP, but looks like a BB squeeze in the works...
  • Bridgemate: @woodman $VKTX $ALT $GPCR $TERN $ALT !!! Thank you!
  • woodman: @MongosPawn $VKTX - watch $TERN too (np).
  • woodman: @mhuie $ETNB - Nice move off the bottom as it is rapidly moving to test that gap from the drop on 10/10. My sense is that many in the obesity space - and related Diabetes/liver/NASH & cardio spaces - are moving on good industry-wide obesity data ...
  • woodman: @curtis $VKTX $ALT - One other thing, if you're looking for a similar pop on obesity data reporting, I believe the only ones in the obesity TA that are reporting data next year are $VKTX $TERN and $GPCR. I believe $VKTX is 1Q24. I need to check on all of that. I think $VKTX offers a good opportunity if I am correct about 1Q24.
  • woodman: @joelsg1 $VKTX $ALT $GPCR - Yep. I mentioned the buyout below and that it applies to the space broadly, IMO. It's a big pie and BP wants in. The assets are with the baby bios - As I mentioned - $VKTX $TERN and $GPCR all have more data coming in 2024.
  • woodman: $TERN whacked over the head after reporting data that seems decent/promising (meeting endpoint) but it's a very tough area to be in with $LLY and $NVO as blue whales. I thankfully held only a very small position, essentially a placeholder, into the data. And I've liked $VKTX's chances - I think its drug is better and safer - better than $TERN, but even with that, my VKTX position is very small currently. My smid biotech $$ are concentrated outside the obesity/metabolic processes/diabetes/NASH area right now.
  • woodman: $NVO $LLY $VKTX $TERN - Some of the second tier obesity/metabolic processes/diabetes companies - e.g. $VKTX $TERN - which have been battered post-diabetes conference (where everyone fell further in love with LLY) are rising on the LLY/NVO tides today. The $TERN $VKTX charts are ugly of late (I have only very small positions to remind me of them), but they have Q3 catalysts coming. I am trying to thread the needle with my biotech $$ with respect to catalysts/timing and shifting around my limited $$, but would consider moving some money into one or both of of VKTX and TERN. But I first want to get some data updates for $XFOR and $INZY. I may not be able to thread the needle, though.
  • woodman: @wijimmy $NANC $KRUZ $QQQ $EFTR - I don't have any more intel on EFTR. I need to look into it. My position remains small. It has two catalysts due this half of the year, but I don't know when. Some others have been of greater immediate interest to me with coming catalysts: $XFOR (I'm very interested - and have a healthy position - in this one with its much anticipated CN data coming this month or next, I'm guessing) and $INZY (one on Wednesday then next Q). $ORIC seems to be making a run into catalysts this half of the year, but I don't have a specific month even. Others of interest include these struggling ones: $TERN (catalysts this Q and another this H), $VKTX (two catalysts this H). $PDSB (one this H).
  • woodman: $VKTX $TERN - both of these NASH / second tier obesity stocks are building bases after significant pullbacks following the June American Diabetes Association conference in which $LLY sucked all the oxygen out of the room regarding its obesity drug. These two stocks seem to have bottomed ahead of coming catalysts (VKTX - obesity Phase 1 data in 2H, but likely Q3 this year, as well X-ALD Phase 1b update H2 this year; TERN Q3 this year for NASH Phase 2a data). I suspect they will rise again into their catalysts.
  • joelsg1: @woodman $VKTX $TERN $LLY Lazarus stocks, think I'll wait but please keep posting about them.
  • woodman: @joelsg1 $VKTX $TERN $LLY - Funny, I traditionally call such stocks "Phoenix" stocks, but same concept. I'm waiting too (I currently have a small VKTX position and even smaller TERN position).
  • woodman: @Lou $PDSB - I have only a placeholder position currently. I had started buying it back but it fell through levels and I didn't like it, so I sold. I'd still like to buy it back for catalysts this half of the year, but I have to thread some needles w ...
  • woodman: $TERN - another one with some Q3 data (NASH) expected to be good. It's stuck under the 200d right now. Like $VKTX got whacked at American Diabetes Association conference where $LLY took all the oxygen out of the room, but this one still has a presences in the big pond. It has tons of cash for a small market cap. $283 million in cash, I think.
  • woodman: @woodman $TERN $VKTX $LLY - presence, not plural. :-?
  • woodman: @joelsg1 $VKTX $ALT - I'm with you. I have only a small reminder position in VKTX as well. It's all about $LLY's obesity drug. Even $PFE out of favor now that it ditched one of its treatments in favor of a two a day pill, but is far behind on a one a ...
  • joelsg1: @woodman $VKTX $ALT $LLY $PFE $TERN Following your lead on these, but obvious concern that the Big Boys' oral formulations will swamp little guys like $VKTX. Also concerned about the thyroid cancer risks being studied, where hopefully $VKTX may have better profile.
  • woodman: @joelsg1 $VKTX $ALT $LLY $PFE $TERN - Very valid concerns. And the small guys are years away. Perhaps a PFE type scoops one of them up in time. Not holding my breath. The need more data.
  • woodman: @joelsg1 $VKTX $ALT $LLY $PFE $TERN - VKTX looks destined for the 11s-12s.
  • phgruver: @woodman $VKTX $ALT $LLY $PFE $TERN $PFE has been in a downtrend for over a year, peaking in Dec 2021. Part of this mimics the market, but the past 6 months, $PFE has definitely under performed. At the current price, the $.41/qtr dividend produces a 4.45% return, something to consider for income in a LT account. As one of the big dogs in that space, I would consider adding, cautiously, to $PFE as a #VALUE play.
  • woodman: Crazy day for bios today, and mostly not in a good way. I've sold a bunch of $VKTX as it has fallen through multiple levels of support. I'll revisit it after some dust settles. There are a lot cross currents in obesity (following the American Diabete ...
  • sierramp: @woodman $VKTX $LLY $NVO $PFE $TERN $XFOR As always, thanks for your informative, well thought post. Appreciate it.
  • woodman: $ORIC gunning for recent high of 6.85. $TERN continues its move off rising support. Potential Russell 3000 additions boost around the corner. (These topics and others discussed on 6/20.)
  • woodman: $TERN; Other small cap Bios/Russell 3000. $TERN had a nice "turn" today. Strong move off rising support drawn from 3/23. This one has some very early data for its obesity drug candidate that will be presented/discussed at the American Diabe ...
  • woodman: $TERN back on course. 20w area has been good support.
  • woodman: NASH & obesity (the next gen ones you don't read about) staying strong. The bulk of my investment here is in $VKTX, though I also have some $ETBN and $TERN.
  • woodman: $VKTX $ETNB $TERN - the NASH/obesity biotechs contintue to move up/back up today.
  • woodman: $TERN is next up (Q3) in the NASH therapeutic area (TA) - for its Phase 2a top line data for TERN-501 (THR-B Agonist) alone and in combo with TERN-101 (FXR Agonist) (DUET trial). Other bios focusing on NASH ($AKRO $MDGL $ETNB $VKTX) have moved well post-NASH-data reporting.
  • camaro69: $TERN HOD
  • woodman: $TERN - I mentioned the move back up yesterday. Today, another monster move. Ride Sally Ride. There was no legit reason for this pullback. It too has NASH and obesity med catalysts coming in Q3 and is yet another run-up play.
  • camaro69: $TERN HOD
  • woodman: @debeers $VKTX - this news is causing others in the therapeutic area to move down - creating an opportunity to buy one like $TERN which will have Q3 data for its NASH candidate. Today's sell off is already reversing.
  • woodman: $XFOR $VKTX - highs of the day. That's more like it. $TERN, nearing the lows (off $VKTX NASH news). I have them all and looking to add to $TERN (which will have Q3 data for NASH as well), but seeing what happens here as it's in cliff-dive mode. Again, these aren't designed as trades for me.
  • steve71: @woodman $XFOR $VKTX $TERN $TERN also has that new $150M ATM news.
  • woodman: @steve71 $XFOR $VKTX $TERN - Sale to Cowen? I see some commentary along these lines now, but nothing official on their website, unless I missed it. I hadn't been aware of it.
  • steve71: $TERN ATM terms. If you weren't sleepy before just wade into this. It's a factor, but not as if all the shares come to market right now.
    "We have entered into a sales agreement, or the May 2023 Sales Agreement, with Cowen and Company, LLC, ...
  • Geewhiz: @steve71 $TERN If they sell the total 150 million dollars at $11 a share it would add 14 million shares to the current share total of 57 million.Hmmmm? Thanks for the info.
  • steve71: @steve71 $TERN And note the $20.4 remaining from the March 2022 Prospectus. Approx 1.9 million shares
  • woodman: @BarryC $NVO - it has cut production due to demand. This is a HUGE market. There will be some pie for a lot of players, even up and comers that are still a few years away. LLY probably holds the crown right now, or will as soon as Mounjaro is approved for obesity. Oral administration will be an important advancement in the space. Up and comers include $MDGL $VKTX $TERN and others. GIP as part of the agonist regime seems to be key.
  • woodman: @woodman $NVO $MDGL $VKTX $TERN https://www.cnbc.com/2023/05/04/novo-nordisk-cuts-some-supply-of-wegovy-drug-amid-soaring-demand.html#:~:text=Novo%20Nordisk%20said%20Thursday%20it,patients%20in%20the%20U.S.%20market.
  • BarryC: @woodman $NVO $MDGL $VKTX $TERN Ty, yes, I was familiar that they had to cut production due to demand. The rest of is WAY over my paygrade, lol... On a different note $NOV is "kinda" a decent set up which is MOST important to me. I will add those symbols and watch more closely, ty for filling me in :-)
  • woodman: $LLY $NOV $VKTX $TERN https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-rivals-see-room-compete-100-bln-weight-loss-drug-market-2023-05-04/?taid=6458e46df925b10001077fa6&utm_campaign=trueanthem&utm_medium=trueanthem&utm_source=twitter
  • woodman: $VKTX - Others in this the NASH family that I own include $TERN and $ETBN. I should have bought $MDGL too, but I don't have it. That said, all of these will move on good news for MDGL which is furthest along out of this group (currently seeking FDA approval) and believed to be a BO target.
  • woodman: $TERN bounce continuation from the pullback to the last breakout area.
  • woodman: $TERN pullback and holding (with a bounce today) the prior resistance (12.41)/now support area. This will move higher if coming data for $VKTX is good and/or more good news for $MDGL comes out. It has data (NASH/obesity) coming in Q3.
  • woodman: $TERN - gunning for $14 (and JMP's PT of $17 - we'll see).
  • woodman: @woodman $TERN JPM, I meant.
  • woodman: $TERN itching to move out of high consolidation. Seems to be getting pulled by the momentum of others in the NASH therapeutic area (TA). See $VKTX $MDGL and perhaps $ETNB.
  • roddog101: @woodman $TERN $VKTX $MDGL $ETNB how long can these keep running? we talking co that dont even have drug to market yet, man they are red hot tho
  • woodman: @roddog101 $TERN $VKTX $MDGL $ETNB - Big Pharma has taken quite an interest in and buying companies with Phase 2 assets in big markets. I think that, in part, is putting wind in VKTX's sails (along with very early Obesity data and other stuff in their pipeline). If the Phase 2b data for its NASH candidate are good, there will be even more speculation that it's an acquisition target.
  • woodman: $TERN $VKTX $MDGL $ETNB - $MRK just bought Prometheus (immunology) before Phase 3 has started. I think there was another recent acquisition of a company with a Phase 2 drug.
  • woodman: $TERN $VKTX $MDGL $ETNB - Bellus was just bought by $GSK which has results through Phase 2, and now is in Phase 3 with no results due this year.
  • roddog101: @woodman $TERN $VKTX $MDGL $ETNB any idea when $VKTX data is coming out? best case worse case scenario?
  • woodman: $TERN $VKTX $MDGL $ETNB - I think it's shortsighted to view VKTX as simply NASH, or even simply as NASH and obesity. They have a lot in the pipeline. An acquiring company would be getting a number of potential assets - 6 programs, 3 or which are in phase 2.
  • woodman: @roddog101 $TERN $VKTX $MDGL $ETNB Coming this Q. I don't know the date. Expected to do well, and it's configuration - GLP-1 and GIP agonist) is expected to significantly lessen the side effects found in others' drug candidates (i.e. nausea and vomiting). There's a high level of excitement.
  • woodman: $TERN - keep an eye on this as it consolidates in the upper BB complex.
  • woodman: $TERN another in the NASH area is in some high consolidation just above prior resistance from Feb-March. May want to keep an eye on this.
  • woodman: $TERN bounce off 21dEMA/prior resistance.
  • woodman: $TERN another NASH stock I'm in is trying to break out. Others I'm in are $VKTX and $ETNB (I'm not in $MDGL but I should be. It's the furthest along among the NASH stocks and is expected to file NDA for accelerated approval this half of the year).
  • zman: $TERN IPO been trading profitably around a core for a couple of weeks. Respects the 200DMA. Enthusiasm high has been surpassed. Holding up well in this market BUT it’s a PHARMA so needs close supervision.
  • zman: $TERN been trading this IPO the past week. I’m up 25%. Watching $24 to add
  • zman: $TERN been trading this for about a week. Got stopped out on initial trade got back in at 17.98 up over 10%. IPO filling the gap up to enthusiasm high. Trailing stops. Pharma.
Visit the Trading Forum to join in the discussion.
Stock Price $20.15
Change -2.09%
Volume 1,420,280

Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases.

Request Video of TERN
Already a member? Sign in here.
Past Month

Leading Peers

Past Month

Lagging Peers

Dan Fitzpatrick

Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:

  • Nightly video Strategy Sessions with a game plan for tomorrow
  • Got a stock you want Dan to look at? Just ask.
  • Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
  • Access to over 90,400 stock analysis videos
  • Access an ever expanding library (90,400) of educational videos that will save you time and make you money

Join a team of friends and traders that have one thing in common; a burning desire to succeed.

Become a Member Today!

Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...

Satisfaction Guaranteed!

Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!